Low-risk prostate cancer cases often upgraded at prostatectomy
A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.
A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.
Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy are advised to receive more aggressive radiation therapy treatment, according to a study.
Variation was observed at a high-volume center when surgeons selected patients with low-risk prostate cancer to undergo radical prostatectomy, according to a study.
Phosphodiesterase type 5 inhibitors up the risk of biochemical recurrence after radical prostatectomy, according to a recent study.
The endorsed guideline outlines use of adjuvant and salvage radiotherapy after surgery for prostate cancer.
For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.
Claims of not receiving proper informed consent and clinical performance are the main issues that arise in radical prostatectomy malpractice lawsuits.
Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.
Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have set forth several recommendations on radiation therapy after prostatectomy.